Soliris



InfusionForHealth.com Ph: 888-777-1945 | Fax: 805-852-2636

Date:	Treatment Lo	cation:	·
PROVIDERS: Please include the following to expedite the order.	Demographics and insurance. Relevant, recent office notes including tried and failed meds. Current medication list. Current CBC & CMP. Positive AChR Antibody test (NMOSD) or Positive AQP4 Antibody test (Myasthenia Gravis) Meningococcal Vaccination: Must initiate vaccine at least 2 weeks prior to first dose MenACWY (2 Doses) Menveo or Menactra Date of 1st/2nd dose: AND MenB-4C (2 Doses) Bexsero Date of 1st/2nd dose: OR MenB-FHbp (3 Doses) Trumenba Date of 1st/2nd/3rd dose:		
PATIENT INFORMATION	N	PRESCRIBER INFOR	RMATION
Patient Name:		Droccribor's Namo	
Patient Contact Number:		Prescriber's Name: Signature:	
DOB:		NPI: Da	ate:
Allergies:		Phone:	Fax:
Weight: lbs / kg Height:		Office Address:	
Diagnosis: ☐ G70.00 Myasthenia gravis without (acute) exacerbation ☐ G70.01 Myasthenia gravis WITH (acute) exacerbation ☐ D59.5 PNH ☐ D59.32 aHUS ☐ G36.0 NMOSD Other Dx/ICD10:		Contact Person:	
		Contact Email:	
Immunize patients with m	eningococcal vaccines at least	2 weeks prior to administe	ering the first dose.
Center will use Hyperse	nsitivity protocol establishe	d by Infusion for Healt	h and P.I.
SOLIRIS DOSAGE			
Date of Last Treatment, I	f Continuation:		
900 mg once weekly f	5, Myasthenia Gravis, and N For 4 weeks, 1200 mg on week For 4 weeks, 900 mg on week	5, then 1200 mg every 2	
☐ Other	mg every		
*Must be enrolled and	authorized in the Soliris-REMS	Program	
	and name product be dispensed, the pre form. If not indicated, Infusion for Health		
	ou DO NOT authorize Infusion for authorization prior to treatment.	Health to order and draw I	labs indicated for clinical
☐ Please check this box if vo	ou DO NOT authorize Infusion for	Health to complete a Pee	r to Peer on behalf of the

prescribing provider for an insurance company that denies authorization for treatment.